| East Coast Biotech Roundup: Maraganore, Flex, NPS, Retrophin, & More | Ben Fidler | 09/15/14 | Boston |
| To Fight Cramps, Christoph Westphal Taps Boston All-Stars for $40M | Ben Fidler | 09/09/14 | Boston |
| John Maraganore: From “Prototypical Geek” To Canny Alnylam Chief | Ben Fidler | 09/07/14 | Boston |
| 7 Takeaways From “What’s Hot in Boston Biotech” | Ben Fidler | 04/22/14 | Boston |
| What’s Hot in Boston Biotech: Here’s the Agenda for April 16 | Ben Fidler | 03/27/14 | Boston |
| Hunting For Brain Plaques, Neurophage Turns to a Virus | Ben Fidler | 01/31/14 | Boston |
| Moderna, Living a Charmed Life, Pulls in Another $125M From Alexion | Luke Timmerman | 01/13/14 | Boston |
| Alnylam Wheels, Deals, and Gets $700M Investment From Genzyme | Ben Fidler | 01/13/14 | Boston |
| Arrowhead Picks Up Where Roche Left Off, Jumps Ahead in RNAi | Luke Timmerman | 12/20/13 | Wisconsin |
| 21 Red Flags to Watch for in a Biotech Company | Luke Timmerman | 10/21/13 | National |
| Alnylam Shares Boom on Early Data For Subcutaneous RNA Drug | Ben Fidler | 07/11/13 | Boston |
| Alnylam Gets $25M From Medicines Co. for Cholesterol Drug | Luke Timmerman | 02/04/13 | Boston |
| Alnylam, Tekmira Look Ahead After RNAi Divorce | Luke Timmerman | 11/14/12 | Boston |
| Alnylam to Pay Tekmira $65M to Settle RNAi Delivery Dispute | Luke Timmerman | 11/12/12 | Boston |
| Brace Yourself: Biotech IPOs Are Beating Tech’s Big Names | Luke Timmerman | 08/13/12 | National |
| Alnylam Stock Climbs on Positive Early Trial for Amyloidosis | Luke Timmerman | 07/16/12 | Boston |
| Join Us for BIO Tweetchat at 12:30 pm ET with John Maraganore | Luke Timmerman | 06/15/12 | National |
| AIDS Drugs Were the Start. Let’s See More FDA Accelerated Approvals | Luke Timmerman | 03/12/12 | National |
| Reinventing Biotech: Meet Corey Goodman, Kevin Starr & More April 3 | Luke Timmerman | 02/23/12 | Seattle |
| Join Kevin Starr, Corey Goodman, Carl Weissman & More in Seattle April 3 | Luke Timmerman | 01/19/12 | Seattle |
| Biology 101 | John Maraganore | 01/18/12 | Boston |
| Alnylam Racing to Prove RNAi Works, For a Disease You’ve Never Heard Of | Luke Timmerman | 12/13/11 | Boston |
| Alnylam and Glaxo Partner on RNAi for Vaccine Production | Arlene Weintraub | 11/01/11 | Boston |
| Celgene Pays Agios $20M, Lycera Adds Cambridge CEO, Getinge Buys Atrium Medical, & More Boston-Area Life Sciences News | Erin Kutz | 10/07/11 | Boston |
| Light Sciences Stumbles, Cardiac Dimensions Gets EU OK, Immune Design Pockets $11M, & More Seattle-Area Life Sciences News | Luke Timmerman | 10/06/11 | Seattle |
| Tweetchat on RNA Interference Upstages iPhone (Not Really, but It Was Still Fun) | Luke Timmerman | 10/05/11 | National |
| Join Us at 1 pm Eastern/10 am Pacific for RNAi “Tweetchat” with Alnylam’s John Maraganore | Luke Timmerman | 10/04/11 | National |
| UW Scores $40M for Biofuels, Cocrystal’s Fight Against HepC, The Women’s Biotech Network, & More Seattle-Area Life Sciences News | Luke Timmerman | 09/29/11 | Seattle |
| Join Us for a Live ‘Tweetchat’ on the Future of RNAi, With Guest John Maraganore of Alnylam | Luke Timmerman | 09/28/11 | National |
| Stirring the Pot Once in a While Doesn’t Hurt, and It Could Help Biotech Break its Malaise | Luke Timmerman | 09/19/11 | National |
